Genuity Science Co-Founder and CSO, Dr. Jeff Gulcher to Present at BioTechX

Dr. Gulcher will present at the Genomics Live! session on November 8th at Europe’s largest congress covering diagnostics, precision medicine and digital transformation in pharmaceutical development and healthcare

Genuity Science, a clinical and genomics data, analytics and insights organisation, will deliver a keynote address at BioTechX Genomics Live! on Tuesday, 8^th November at 9.20am CET. The conference, formerly known as BioData EU / Genomics Live!, will be held in Basel, Switzerland November 8^th – 11^th, 2022.

This 20-minute presentation will focus on:

The unmet need of highly detailed and longitudinal clinical data in large-scale human genetics studies to define more severe patient subsets of common disease which cause the most morbidity and mortality.
The lack of clinical subtype and supportive clinical data in current genetic studies which prevent our understanding of more severe and rapidly progressive subtypes of disease.
The benefits of whole genome sequence data together with detailed clinical data in human genetic studies to better illuminate disease biology, using common cardiometabolic and CNS diseases as examples.

Title: Accelerating Precision Medicine in Cardiometabolic and CNS Diseases: Drug Target discovery from large cohorts with WGS, longitudinal clinical data, and disease tissue snRNA sequencing

Presenter: Jeffrey Gulcher, M.D., Ph.D., Co-Founder and Chief Scientific Officer, Genuity Science

Session: Genomics Live! Main Stage

Time/Date: Tuesday, 8^th November, 9.20am CET

Dr. Gulcher, a longstanding scientific leader in the field of genomics, co-founded NextCODE, the precurser to Genuity Science, in 2013 following on from ground-breaking massive-scale population genetics work conducted in Iceland at deCODE genetics, a company that he co-founded with Dr. Kári Stefánsson in 1996.

Gulcher previously served as a neurologist at Beth Israel Hospital and Harvard Medical School and received his PhD. and M.D. from the University of Chicago. He has authored more than 200 peer-reviewed publications on the genetics of common/complex diseases.

BioTechX successfully brings together an amalgamation of genomics, translational medicine, data scientists, IT, bioinformaticians, cheminformaticians, clinicians, healthcare and pharma companies. The event, established in 2018, showcases innovation and demonstrated in genomics and big data.

To learn more about the conference and how to register, visit https://www.terrapinn.com/conference/biotechx/